Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapy

@article{Kyriakidis2016EstrogenRB,
  title={Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapy},
  author={Ioannis Kyriakidis and Paraskevi Papaioannidou},
  journal={Archives of Gynecology and Obstetrics},
  year={2016},
  volume={293},
  pages={1161-1168}
}
AbstractIntroduction Ovarian cancer remains the leading cause of mortality due to gynecological tumors. Estrogen receptors (ERs) seem to participate in tumor progression even in the absence of estrogens. Twenty years after the cloning of the second estrogen receptor, a wide spectrum of studies have shown its implication in both physiologic and pathologic pathways. ERβ, being the predominant type of ER in normal ovary tissue, has not only been linked with pathogenesis of ovarian cancer, but also… Expand
Estrogen receptor β in cancer: to β(e) or not to β(e)?
TLDR
While ERβ exhibits anti-tumor activity in breast, ovarian, and prostate cancer, its expression is associated with disease progression and worse prognosis in lung cancer. Expand
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
TLDR
In vitro studies demonstrate that ERβ ligands inhibit the proliferation of melanoma cells harboring the NRAS (but not the BRAF) mutation, suggesting that ERα activation might impair melanoma development through the inhibition of the PI3K/Akt pathway, and suggest that ER β agonists might be considered as an effective treatment strategy, in combination with MAPK inhibitors, for NRAS mutant melanomas. Expand
Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications
TLDR
The role of hormones (GnRH, gonadotropins, androgens, estrogens and progestins) and their receptors in OC tumorigenesis, and hormonal therapy in OC treatment is discussed and summarized. Expand
Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor α in ovarian cancer
TLDR
A feed‐forward mechanism that sustains activation of the CXCR7/CXCL11 axis under ERα control to induce the epithelial–mesenchymal transition pathway and metastatic behavior of OC cells is identified. Expand
Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells
BackgroundEstrogen receptor (ER) β has been suggested to affect ovarian carcinogenesis. We examined the effects of four ERβ agonists on proliferation and gene expression of two ovarian cancer cellExpand
Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium.
TLDR
A pooled analysis of 7 nested case-control studies in the Ovarian Cancer Cohort Consortium provides further evidence for a role of hormone-related pathways in EOC risk, with differences in associations between androgens and histologic subtypes of EOC. Expand
FRBI suppresses carcinogenesis of uterine cancers by regulating expressions of FHIT, PTEN and ARID1A
TLDR
FRBI treatment could promote the production of FHIT and ARID1A, and also accelerate expression levels of F HIT proteins and mRNA in mice uterine tissues, and provided potential biomarker for diagnosing uterine cancer. Expand
The expression of transcription factor BORIS and its association with the estrogen receptor beta (ER-β) in cervical carcinogenesis.
TLDR
The results suggest synergistic roles for BORis and ER-β during cervical cancer progression with a possible regulation of the estrogen receptors by BORIS in the development of cervical cancer; however, more detailed studies are needed to confirm this suggestion and to determine the precise role of BORIs in cervical cancer. Expand
FSH receptor binding inhibitor restrains follicular development and possibly attenuates carcinogenesis of ovarian cancer through down-regulating expression levels of FSHR and ERβ in normal ovarian tissues.
TLDR
A high dose of FRBI could suppress ovarian and follicular development, and attenuate expression levels of ERβ and FSHR mRNAs and proteins in the ovaries, additionally inhibit E2 production. Expand
Endometriosis Malignant Transformation: Epigenetics as a Probable Mechanism in Ovarian Tumorigenesis
TLDR
The research progress about the current knowledge regarding the epigenetic modifications of the relations between endometriosis malignant transformation and ovarian cancer is summarized in an effort to identify some risk factors probably associated with ectopic endometrium transformation. Expand
...
1
2
...

References

SHOWING 1-10 OF 78 REFERENCES
Potential Role of Estrogen Receptor Beta as a Tumor Suppressor of Epithelial Ovarian Cancer
TLDR
Evidence is presented that reintroduction of ERβ in BG-1 epithelial ovarian cancer cells, which express ERα, leads in vitro to a decrease of basal and estradiol-promoted cell proliferation, unveiling a potential tumor-suppressor role of ER β in ovarian carcinogenesis. Expand
Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.
TLDR
The characterization of estrogen receptor beta brought new insight into the mechanisms underlying estrogen signaling, and the potential distinct roles of ERalpha and ERbeta expression in carcinogenesis, as suggested by experimental and clinical data are discussed in this review. Expand
Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients.
TLDR
The loss of ERβ expression in ovarian tumours may be a feature of malignant transformation and is associated with poorer overall survival time in patients with progressive disease. Expand
Estrogen Receptor Subtypes in Ovarian Cancer: A Clinical Correlation
TLDR
Loss of ER&bgr; expression in ovarian tumors may be a feature of malignant transformation and help improve response to hormonal therapy by tailoring the use of selective estrogen receptor modulators with different ER affinity in selected women. Expand
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival12
TLDR
Findings demonstrate a prognostic role for PR and AR in ovarian cancer and support that tumors should be stratified based on molecular as well as histological subtypes in future studies investigating the role of endocrine treatment in ovariancancer. Expand
Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival
TLDR
ER-α/-β and PR-A/-B are frequently expressed in OC with a certain variability relating to histological subtype, grade and stage, and may be useful targets for a more individualized OC therapy. Expand
Mitochondrial estrogen receptor β2 drives antiapoptotic pathways in advanced serous ovarian cancer.
TLDR
In vivo mechanistic evidence for an antiapoptotic function of mitochondrial ERβ2 is provided, a finding supporting the value of its cytoplasmic expression as an unfavorable prognostic biomarker for serous ovarian cancer. Expand
Hormone receptors as a marker of poor survival in epithelial ovarian cancer.
TLDR
Hormone receptors are expressed in the majority of ovarian cancer tumors and may serve as therapeutic targets and may prove valuable in selecting patients for endocrine therapy. Expand
Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis.
TLDR
Recent data suggesting a possible tumor-suppressor role for ERbeta in ovarian carcinogenesis are discussed and restoration of ER beta in ovarian cancer cells, leads to strong inhibition of their proliferation and invasion, while apoptosis is enhanced. Expand
Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells
TLDR
It is suggested that estrogens, signaling via either or both ER subtypes, may play an indispensable role in regulating normal HOSE cell functions, and loss of ERα, PR, and AR mRNA expression in HOSE cells may be responsible for neoplastic transformation in this cell type. Expand
...
1
2
3
4
5
...